

## **SUPPLEMENTAL MATERIAL**

### **Table of Contents of Supplemental Material**

**Supplemental Table 1.** CPRD codes for nephrotic syndrome and the clinical events

**Supplemental Table 2.** The Anatomical Therapeutic Chemical Classification system for NSAIDs

**Supplemental Table 3.** Odds ratios of nephrotic syndrome for nonsteroidal anti-inflammatory drug (NSAID) users stratified by age

**Supplemental Table 4.** Odds ratios of nephrotic syndrome for NSAID users stratified by sex

**Supplemental Table 5.** Odds ratios of nephrotic syndrome defined by kidney biopsy for conventional NSAID users

**Supplemental Table 6.** Odds ratios of nephrotic syndrome for conventional NSAID users 3 months before the index date

**Supplemental Table 7.** Odds ratios of nephrotic syndrome for conventional NSAID users 6 months before the index date

**Supplemental Table 8.** Odds ratios of nephrotic syndrome for conventional NSAID users 9 months before the index date

**Supplemental Table 9.** Odds ratios of nephrotic syndrome for conventional NSAID users 12 months before the index date

**Supplemental Table 10.** Odds ratios of nephrotic syndrome for conventional NSAID users among those without comorbidities that are well-known causes of nephrotic syndrome

**Supplemental Table 11.** Odds ratios of hospitalized patients with nephrotic syndrome for conventional NSAID users

**Supplemental Table 1.** CPRD codes for nephrotic syndrome and the clinical events

| No | Med code | Read code | Read term  | Frequency, n (%) |
|----|----------|-----------|--|------------------|
| 1  | 2999     | K01..00   | NS   | 1972 (75)        |
| 2  | 2471     | K01X100   | NS in DM   | 172 (7)          |
| 3  | 22205    | K01X411   | Lupus nephritis  | 138 (5)          |
| 4  | 1803     | K011.00   | NS with membranous glomerulonephritis                      | 78 (3)           |
| 5  | 22852    | K015.00   | NS, focal and segmental glomerular lesions                 | 69 (3)           |
| 6  | 17365    | K01B.00   | NS, diffuse crescentic glomerulonephritis                  | 31 (1)           |
| 7  | 29634    | K013.00   | NS with minimal change glomerulonephritis                  | 28 (1)           |
| 8  | 21989    | K019.00   | NS, diffuse mesangio-capillary glomerulonephritis          | 25 (1)           |
| 9  | 27427    | K01z.00   | NS NOS   | 24 (1)           |
| 10 | 19316    | K016.00   | NS, diffuse membranous glomerulonephritis                  | 20 (1)           |
| 11 | 21947    | K017.00   | NS, diffuse mesangial proliferative glomerulonephritis     | 17 (1)           |
| 12 | 23913    | K014.00   | NS, minor glomerular abnormality                           | 12 (1)           |
| 13 | 47922    | K01x000   | NS in amyloidosis  | 10 (0)           |
| 14 | 47672    | K01x400   | NS in systemic lupus erythematosus                         | 9 (0)            |
| 15 | 50472    | K018.00   | NS, diffuse endocapillary proliferative glomerulonephritis | 3 (0)            |
| 16 | 45499    | K01X111   | Kimmelstiel-Wilson Disease                                 | 2 (0)            |
| 17 | 56987    | K01A.00   | NS, dense deposit disease                                  | 2 (0)            |
| 18 | 57926    | K013.12   | Steroid sensitive NS                                       | 2 (0)            |
| 19 | 108816   | K01x.00   | NS in diseases EC  | 2 (0)            |
| 20 | 40349    | K013.11   | Lipoid nephrosis   | 1 (0)            |
| 21 | 58750    | K01x300   | NS in poly-arthritis nodosa                                | 1 (0)            |
| 22 | 94373    | K01y.00   | NS with other pathological kidney lesions                  | 1 (0)            |
| 23 | 110794   | K01w200   | Congenital NS with focal glomerulosclerosis                | 1 (0)            |
| 24 | 63786    | K01w.00   | Congenital NS  | 0 (0)            |
| 25 | 72303    | K01w000   | Finnish NS   | 0 (0)            |
| 26 | 9840     | K010.00   | NS with proliferative glomerulonephritis                   | 0 (0)            |
| 27 | 99201    | K01x200   | NS in malaria  | 0 (0)            |
| 28 | 99644    | K012.00   | NS + membrano-proliferative glomerulonephritis             | 0 (0)            |
| 29 | 108591   | K01w100   | Drash syndrome   | 0 (0)            |
| 30 | 108922   | K01w112   | Wilms' tumor + NS + pseudohermaphroditism                  | 0 (0)            |
| 31 | 111370   | K01wz00   | Congenital NS NOS  | 0 (0)            |
|    |          |           | TOTAL  | 2620 (100)       |

CPRD = the Clinical Practice Research Datalink; DM = diabetes mellitus; EC = elsewhere classified; NS = nephrotic syndrome; NOS = Not Otherwise specified;

**Supplemental Table 2.** The Anatomical Therapeutic Chemical Classification system for NSAIDs

| No | NSAIDs according to COX enzyme selectivity and chemical structures | ATC codes |
|----|--|-----------|
| 1  | Conventional NSAIDs  |           |
|    | Butylpyrazolidines   | M01AA     |
|    | Acetic acid derivatives and related substances                     | M01AB     |
|    | Oxicams  | M01AC     |
|    | Propionic acid derivatives   | M01AE     |
|    | Fenamates  | M01AG     |
|    | Other anti-inflammatory and anti-rheumatoid agents, non-steroid    | M01AX     |
| 2  | Selective COX-2 inhibitors   | M01AH     |

Abbreviations: ATC = The Anatomical Therapeutic Chemical; COX = cyclooxygenase; NSAIDs = non-steroidal anti-inflammatory drugs

**Supplemental Table 3.** Odds ratios of nephrotic syndrome for NSAID users stratified by age

| <b>18-64 years old</b>   | Cases<br>(n = 1,579) | Controls<br>(n = 6,316) | Crude OR<br>(95% CI) | Adj. OR <sup>‡</sup><br>(95% CI) |
|--|----------------------|-------------------------|----------------------|----------------------------------|
| Nonuse, n (%)  | 715 (45)             | 3,375 (53)              | 1                    | 1                                |
| Current use, n (%)   |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 40 (3)               | 123 (2)                 | 1.54 (1.07-2.13)     | 1.08 (0.69-1.68)                 |
| Selective COX-2 inhibitors   | 6 (0)                | 20 (0)                  | 1.42 (0.57-3.54)     | 0.38 (0.21-0.70)                 |
| Recent use, n (%)  |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 47 (3)               | 91 (1)                  | 2.44 (1.70-3.50)     | 1.59 (1.03-2.47)                 |
| Selective COX-2 inhibitors   | 2 (0)                | 5 (0)                   | NA                   | NA                               |
| Past use (discontinuation<br>between 2 months – 2 years), n<br>(%) |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 300 (19)             | 900 (14)                | 1.57 (1.35-1.84)     | 1.13 (0.94-1.36)                 |
| Selective COX-2 inhibitors   | 17 (1)               | 25 (0)                  | 3.21 (1.72-5.98)     | 1.43 (0.92-2.23)                 |
| Past use (discontinuation >2<br>years), n (%)                      |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 443 (28)             | 1734 (28)               | 1.21 (1.06-1.38)     | 0.91 (0.77-1.07)                 |
| Selective COX-2 inhibitors   | 9 (1)                | 43 (1)                  | 0.99 (0.48-2.04)     | 0.32 (0.13-0.80)                 |
| <b>≥65 years old</b>   | Cases<br>(n = 1041)  | Controls<br>(n = 4138)  | Crude OR<br>(95% CI) | Adj. OR <sup>‡</sup><br>(95% CI) |
| Nonuse, n (%)  | 403 (39)             | 1,767 (43)              | 1                    | 1                                |
| Current use, n (%)   |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 34 (3)               | 141 (3)                 | 1.06 (0.72-1.56)     | 1.02 (0.67-1.55)                 |
| Selective COX-2 inhibitors   | 2 (0)                | 19 (1)                  | NA                   | NA                               |
| Recent use, n (%)  |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 26 (3)               | 92 (2)                  | 1.25 (0.80-1.96)     | 1.31 (0.80-2.15)                 |
| Selective COX-2 inhibitors   | 2 (0)                | 10 (0)                  | NA                   | NA                               |
| Past use (discontinuation<br>between 2 months – 2 years), n<br>(%) |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 174 (17)             | 577 (14)                | 1.32 (1.08-1.62)     | 1.26 (1.01-1.58)                 |
| Selective COX-2 inhibitors   | 20 (2)               | 74 (2)                  | 1.19 (0.72-1.97)     | 1.15 (0.67-1.98)                 |
| Past use (discontinuation >2<br>years), n (%)                      |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 354 (34)             | 1,369 (33)              | 1.13 (0.97-1.33)     | 0.97 (0.81-1.16)                 |
| Selective COX-2 inhibitors   | 26 (3)               | 90 (2)                  | 1.27 (0.81-1.99)     | 0.98 (0.59-1.62)                 |

Abbreviations: CI = confidence interval; COX-2 = cyclooxygenase-2; NA = non-applicable; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>‡</sup>adjusted for comorbidities, co-medications, body mass index, smoking, and alcohol abuse

**Supplemental Table 4.** Odds ratios of nephrotic syndrome for NSAID users stratified by sex

| <b>Female</b>  | Cases<br>(n = 1,432) | Controls<br>(n = 5,714) | Crude OR<br>(95% CI) | Adj. OR <sup>‡</sup><br>(95% CI) |
|--|----------------------|-------------------------|----------------------|----------------------------------|
| Nonuse, n (%)  | 639 (45)             | 2984 (52)               | 1                    | 1                                |
| Current use, n (%)   |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 33 (2)               | 130 (2)                 | 1.19 (0.80-1.75)     | 1.15 (0.92-1.44)                 |
| Selective COX-2 inhibitors   | 18 (0)               | 18 (0)                  | 0.78 (0.23-2.65)     | 0.51 (0.27-0.97)                 |
| Recent use, n (%)  |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 40 (3)               | 94 (2)                  | 1.99 (1.36-2.91)     | 1.80 (1.17-2.79)                 |
| Selective COX-2 inhibitors   | 2 (0)                | 2 (0)                   | NA                   | NA                               |
| Past use (discontinuation<br>between 2 months – 2 years),<br>n (%) |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 240 (17)             | 722 (13)                | 1.55 (1.31-1.84)     | 1.35 (1.11-1.63)                 |
| Selective COX-2 inhibitors   | 54 (2)               | 54 (1)                  | 2.08 (1.27-3.38)     | 1.91 (1.24-2.94)                 |
| Past use (discontinuation >2<br>years), n (%)                      |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 433 (30)             | 1654 (29)               | 1.22 (1.07-1.40)     | 1.02 (0.87-1.20)                 |
| Selective COX-2 inhibitors   | 56 (1)               | 56 (1)                  | 1.58 (0.94-2.69)     | 0.98 (0.53-1.81)                 |
|  |                      |                         |                      |                                  |
| <b>Male</b>  | Cases<br>(n = 1,188) | Controls<br>(n = 4,740) | Crude OR<br>(95% CI) | Adj. OR <sup>‡</sup><br>(95% CI) |
| Nonuse, n (%)  | 479 (40)             | 2158 (46)               | 1                    | 1                                |
| Current use, n (%)   |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 41 (4)               | 134 (3)                 | 1.38 (0.96-1.98)     | 1.07 (0.70-1.64)                 |
| Selective COX-2 inhibitors   | 5 (0)                | 21 (0)                  | 1.07 (0.40-2.86)     | 0.26 (0.06-1.15)                 |
| Recent use, n (%)  |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 33 (3)               | 88 (2)                  | 1.69 (1.12-2.55)     | 1.31 (0.79-2.18)                 |
| Selective COX-2 inhibitors   | 3 (0)                | 13 (0)                  | NA                   | NA                               |
| Past use (discontinuation<br>between 2 months – 2 years),<br>n (%) |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 234 (20)             | 755 (16)                | 1.40 (1.17-1.67)     | 1.12 (0.91-1.39)                 |
| Selective COX-2 inhibitors   | 13 (1)               | 45 (1)                  | 1.30 (0.70-2.43)     | 0.52 (0.21-1.28)                 |
| Past use (discontinuation >2<br>years), n (%)                      |                      |                         |                      |                                  |
| Conventional NSAIDs <sup>1</sup>                                   | 364 (31)             | 1449 (31)               | 1.13 (0.97-1.32)     | 0.90 (0.75-1.09)                 |
| Selective COX-2 inhibitors   | 16 (1)               | 77 (2)                  | 0.94 (0.54-1.62)     | 0.62 (0.33-1.17)                 |

Abbreviations: CI = confidence interval; COX-2 = cyclooxygenase-2; NA = non-applicable; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>‡</sup>adjusted for comorbidities, co-medications, body mass index, smoking, and alcohol abuse

**Supplemental Table 5.** Odds ratios of nephrotic syndrome defined by kidney biopsy for conventional NSAID<sup>1</sup> users

|  | Cases<br>(n = 279) | Controls<br>(n = 10,168) | Crude OR<br>(95% CI) | Adj. OR <sup>‡</sup><br>(95% CI) |
|--|--------------------|--------------------------|----------------------|----------------------------------|
| Nonuse, n (%)  | 121 (43)           | 5142 (51)                | 1                    | 1                                |
| Current use, n (%)                                   | 7 (3)              | 264 (3)                  | 1.13 (0.52-2.44)     | 1.06 (0.47-2.37)                 |
| Recent use, n (%)                                    | 10 (4)             | 182 (2)                  | 2.35 (1.21-4.51)     | 1.83 (0.89-3.80)                 |
| Past use (stopped between 2 months – 2 years), n (%) | 49 (18)            | 1477 (15)                | 1.41 (1.01-1.98)     | 1.23 (0.85-1.78)                 |
| Past use (stopped >2 years), n (%)                   | 92 (33)            | 3103 (31)                | 1.26 (0.96-1.66)     | 1.09 (0.80-1.49)                 |

Abbreviations: CI = confidence interval; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>‡</sup>adjusted for matching variables (age, sex, the general practitioner practice, and index-date), comorbidities, co-medications, body mass index, smoking, and alcohol abuse

**Supplemental Table 6.** Odds ratios of nephrotic syndrome for conventional NSAID users<sup>1</sup> 3 months before the index date

|   | Cases<br>(n =2,536) | Controls<br>(n = 10,168) | Crude OR<br>(95% CI) | Adjusted OR <sup>‡</sup><br>(95% CI) |
|---|---------------------|--------------------------|----------------------|--------------------------------------|
| Nonuse, n (%)   | 1147 (45)           | 5208 (51)                | 1                    | 1                                    |
| Current use <sup>♢</sup> , n (%)                                    |                     |                          |                      |                                      |
| 1-14 days   | 36 (1)              | 96 (1)                   | 1.70 (1.15-2.51)     | 1.38 (0.89-2.13)                     |
| 15-28 days  | 29 (1)              | 95 (1)                   | 1.38 (0.91-2.11)     | 1.24 (0.79-1.97)                     |
| >28 days  | 26 (1)              | 66 (1)                   | 1.79 (1.13-2.82)     | 1.77 (1.09-2.89)                     |
| Recent use, n (%)   | 71 (3)              | 177 (2)                  | 1.82 (1.37-2.41)     | 1.78 (1.31-2.43)                     |
| Past use (discontinuation<br>between >2 months – 2<br>years), n (%) | 445 (18)            | 1504 (15)                | 1.34 (1.19-1.52)     | 1.19 (1.03-1.36)                     |
| Past use (discontinuation >2<br>years), n (%)                       | 782 (31)            | 3022 (30)                | 1.17 (1.06-1.30)     | 1.03 (0.92-1.15)                     |

Abbreviations: CI = confidence interval; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>♢</sup>duration of use

<sup>‡</sup>adjusted for matching variables (age, sex, general practitioners' practice, and the index date), comorbidities, co-medications, body mass index, smoking behavior, and alcohol abuse

**Supplemental Table 7.** Odds ratios of nephrotic syndrome for conventional NSAID users<sup>1</sup> 6 months before the index date

|   | Cases<br>(n =2,536) | Controls<br>(n = 10,168) | Crude OR<br>(95% CI) | Adjusted OR <sup>‡</sup><br>(95% CI) |
|---|---------------------|--------------------------|----------------------|--------------------------------------|
| Nonuse, n (%)   | 1179 (46)           | 5265 (52)                | 1                    | 1                                    |
| Current use <sup>♠</sup> , n (%)                                    |                     |                          |                      |                                      |
| 1-14 days   | 37 (2)              | 117 (1)                  | 1.42 (0.98-2.07)     | 1.32 (1.31-1.34)                     |
| 15-28 days  | 44 (2)              | 123 (1)                  | 1.61 (1.13-2.28)     | 1.45 (1.00-2.12)                     |
| >28 days  | 23 (1)              | 47 (1)                   | 2.20 (1.33-3.63)     | 2.03 (1.17-3.52)                     |
| Recent use, n (%)   | 48 (2)              | 193 (2)                  | 1.09 (0.79-1.51)     | 0.89 (0.62-1.27)                     |
| Past use (discontinuation<br>between >2 months – 2<br>years), n (%) | 448 (18)            | 1487 (15)                | 1.35 (1.20-1.53)     | 1.22 (1.06-1.39)                     |
| Past use (discontinuation >2<br>years), n (%)                       | 758 (30)            | 2936 (29)                | 1.16 (1.05-1.28)     | 1.03 (0.92-1.15)                     |

Abbreviations: CI = confidence interval; COX-2 = cyclooxygenase-2; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>♠</sup>duration of use

<sup>‡</sup>adjusted for matching variables (age, sex, general practitioners' practice, and the index date), comorbidities, co-medications, body mass index, smoking behavior, and alcohol abuse

**Supplemental Table 8.** Odds ratios of nephrotic syndrome for conventional NSAID users<sup>1</sup> 9 months before the index date

|   | Cases<br>(n = 2,536) | Controls<br>(n = 10,168) | Crude OR<br>(95% CI) | Adjusted OR <sup>‡</sup><br>(95% CI) |
|---|----------------------|--------------------------|----------------------|--------------------------------------|
| Nonuse, n (%)   | 1202 (47)            | 5323 (52)                | 1                    | 1                                    |
| Current use <sup>Φ</sup> , n (%)                                    |                      |                          |                      |                                      |
| 1-14 days   | 35 (1)               | 128 (1)                  | 1.22 (0.83-1.78)     | 1.16 (0.77-1.73)                     |
| 15-28 days  | 53 (2)               | 113 (1)                  | 2.09 (1.50-2.91)     | 2.13 (1.49-3.04)                     |
| >28 days  | 27 (1)               | 64 (1)                   | 1.88 (1.19-2.96)     | 1.60 (0.97-2.62)                     |
| Recent use, n (%)   | 57 (2)               | 180 (2)                  | 1.41 (1.04-1.91)     | 1.21 (0.87-1.68)                     |
| Past use (discontinuation<br>between >2 months – 2<br>years), n (%) | 426 (17)             | 1492 (15)                | 1.27 (1.12-1.44)     | 1.15 (1.00-1.31)                     |
| Past use (discontinuation >2<br>years), n (%)                       | 736 (29)             | 2868 (28)                | 1.14 (1.03-1.27)     | 1.01 (0.90-1.14)                     |

Abbreviations: CI = confidence interval; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>Φ</sup>duration of use

<sup>‡</sup>adjusted for matching variables (age, sex, general practitioners' practice, and the index date), comorbidities, co-medications, body mass index, smoking behavior, and alcohol abuse

**Supplemental Table 9.** Odds ratios of nephrotic syndrome for conventional NSAID users<sup>1</sup> 12 months before the index date

|   | Cases<br>(n = 2,536) | Controls<br>(n = 10,168) | Crude OR<br>(95% CI) | Adjusted OR <sup>‡</sup><br>(95% CI) |
|---|----------------------|--------------------------|----------------------|--------------------------------------|
| Nonuse, n (%)   | 1215 (48)            | 5413 (53)                | 1                    | 1                                    |
| Current use <sup>Φ</sup> , n (%)                                    |                      |                          |                      |                                      |
| 1-14 days   | 46 (2)               | 116 (1)                  | 1.77 (1.25-2.50)     | 1.56 (1.07-2.27)                     |
| 15-28 days  | 31 (1)               | 116 (1)                  | 1.19 (0.80-1.78)     | 1.14 (0.75-1.75)                     |
| >28 days  | 24 (1)               | 55 (1)                   | 1.94 (1.20-3.15)     | 1.51 (0.89-2.56)                     |
| Recent use, n (%)   | 62 (2)               | 165 (2)                  | 1.67 (1.24-2.26)     | 1.51 (1.09-2.08)                     |
| Past use (discontinuation<br>between >2 months – 2<br>years), n (%) | 428 (17)             | 1510 (15)                | 1.26 (1.12-1.43)     | 1.13 (0.99-1.29)                     |
| Past use (discontinuation >2<br>years), n (%)                       | 730 (29)             | 2795 (27)                | 1.16 (1.05-1.29)     | 1.04 (0.93-1.16)                     |

Abbreviations: CI = confidence interval; COX-2 = cyclooxygenase-2; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>Φ</sup>duration of use

<sup>‡</sup>adjusted for matching variables (age, sex, general practitioners' practice, and the index date), comorbidities, co-medications, body mass index, smoking behavior, and alcohol abuse

**Supplemental Table 10.** Odds ratios of nephrotic syndrome for conventional NSAID users among those without comorbidities<sup>1</sup> that are well-known causes of nephrotic syndrome

|   | Cases<br>(n = 1,785) | Controls<br>(n = 9,373) | Crude OR<br>(95% CI) | Adj. OR <sup>‡</sup><br>(95% CI) |
|---|----------------------|-------------------------|----------------------|----------------------------------|
| Nonuse, n (%)   | 815 (46)             | 4859 (52)               | 1                    | 1                                |
| Current use <sup>Φ</sup> , n (%)                                    |                      |                         |                      |                                  |
| 1-14 days   | 18 (1)               | 91 (1)                  | 1.18 (0.71-1.97)     | 0.91 (0.52-1.60)                 |
| 15-28 days  | 23 (1)               | 99 (1)                  | 1.39 (0.88-2.19)     | 1.41 (0.86-2.31)                 |
| >28 days  | 14 (1)               | 47 (1)                  | 1.78 (0.97-3.24)     | 1.60 (0.83-3.10)                 |
| Recent use, n (%)   | 51 (3)               | 166 (2)                 | 1.83 (1.33-2.53)     | 1.66 (1.16-2.39)                 |
| Past use (discontinuation<br>between >2 months – 2<br>years), n (%) | 331 (19)             | 1346 (14)               | 1.47 (1.27-1.69)     | 1.29 (1.10-1.51)                 |
| Past use (discontinuation >2<br>years), n (%)                       | 533 (30)             | 2765 (30)               | 1.15 (1.02-1.29)     | 1.01 (0.88-1.16)                 |

Abbreviations: Adj. = Adjusted; CI = confidence interval; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis, amyloidosis, and leukemia

<sup>Φ</sup>duration of use

<sup>‡</sup>adjusted for matching variables (age, sex, general practitioners' practice, and the index date), comorbidities associated with kidney toxicity, co-medications, body mass index, smoking, and alcohol abuse

**Supplemental Table 11.** Odds ratios of hospitalized patients with nephrotic syndrome for conventional NSAID<sup>1</sup> users

|   | Cases<br>(n = 680) | Controls<br>(n = 10,168) | Crude OR<br>(95% CI) | Adj. OR <sup>‡</sup><br>(95% CI) |
|---|--------------------|--------------------------|----------------------|----------------------------------|
| Nonuse, n (%)   | 276 (41)           | 5142 (51)                | 1                    | 1                                |
| Current use <sup>Φ</sup> , n (%)                                    |                    |                          |                      |                                  |
| 1-14 days   | 6 (1)              | 104 (1)                  | 1.08 (0.47-2.47)     | 0.83 (0.35-1.97)                 |
| 15-28 days  | 9 (1)              | 104 (1)                  | 1.61 (0.81-3.22)     | 1.61 (0.78-3.32)                 |
| >28 days  | 6 (1)              | 56 (1)                   | 2.00 (0.85-4.67)     | 1.53 (0.59-3.95)                 |
| Recent use, n (%)   | 19 (3)             | 182 (2)                  | 1.95 (1.19-3.17)     | 1.52 (0.89-2.59)                 |
| Past use (discontinuation<br>between >2 months – 2<br>years), n (%) | 130 (19)           | 1477 (15)                | 1.64 (1.32-2.04)     | 1.27 (1.00-1.61)                 |
| Past use (discontinuation >2<br>years), n (%)                       | 234 (34)           | 3103 (31)                | 1.41 (1.17-1.68)     | 1.06 (0.87-1.30)                 |

Abbreviations: CI = confidence interval; COX-2 = cyclooxygenase-2; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; OR = Odds ratio

<sup>1</sup>acetic acid derivatives, propionic acid derivatives, fenamates, oxicams, and other NSAIDs

<sup>Φ</sup>duration of use

<sup>‡</sup>adjusted for matching variables (age, sex, general practitioners' practice, and the index date), comorbidities, co-medications, body mass index, smoking, and alcohol abuse